A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Myron Czuczman, MD
Celgene
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
90 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mater Private Medical Centre - Haematology and Oncology Clinics of Australasia Research Centre
South Brisbane, Queensland, Australia
- Peter Maccallum Cancer Centre
East Melbourne, Australia
- St. Vincent Hospital
Fitzroy, Australia
- Royal North Shore Hospital
St Leonards, Australia
- University Hospital Brno
Brno, Czechia
- University Hospital Hradec Kralove
Hradec Králové, Czechia
- Charles University General Hospital
Prague, Czechia
- University Hospital of Kralovske Vinohrady
Prague, Czechia
- Polyclinique Bordeaux Nord Aquitaine
Bordeaux, France
- Hopital Henri Mondor
Créteil, France
- Hopital Claude Huriez
Lille, France
- Chu Nantes Hotel Dieu
Nantes, France
- Hopital Saint-Louis
Paris, France
- Service Des Maladies Du Sang
Pessac, France
- Centre Hospitalier Lyon Sud
Pierre-Bénite, France
- Centre Eugene Marquis
Rennes, France
- Centre Henri Becquerel
Rouen, France
- Charite Universitatsmedizin Berlin Campus Virchow Klinikum Centrum Fur Tumormedizin
Berlin, Germany
- Uniklinik Koln
Cologne, Germany
- Krankenhaus Nordwest
Frankfurt a.M., Germany
- Georg-August-Universität Göttingen
Göttingen, Germany
- Klinikum Der Universitat Munchen-Grosshadern
München, Germany
- Klinikum Nurnberg Nord
Nuremberg, Germany
- Ukt Universitaetsklinikum Tuebingen
Tübingen, Germany
- Klinika Hematologii Akademickie Centrum Kliniczne Akademii Medycznej W Gdansku
Gdansk, Poland
- Oddzial Kliniczny Kliniki Hematologii
Krakow, Poland
- Wojewodzki Szpital Specjalistczny Im. Mikolaja Kopernika
Lodz, Poland
- Klinika Nowotworow Ukladu Chlonnego
Warsaw, Poland
- Hospital Universitario Vall D Hebron
Barcelona, Spain
- Hospital Universitario la Paz
Madrid, Spain
- Hospital de la Princesa
Madrid, Spain
- Clinica Universitaria de Navarra
Pamplona, Spain
- Hospital Universitario de Salamanca
Salamanca, Spain
- Hospital Marques de Valdecilla
Santandar, Spain
- Lund University Hosptial
Lund, Sweden
- Akademiska Sjukhuset
Uppsala, Sweden
- Dnipropetrovsk State Medical Academy
Dnipropetrovsk, Ukraine
- National Cancer Institute Department of Conservative Methods of Treatment
Kyiv, Ukraine
- R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
Kyiv, Ukraine
- Institute of Blood Pathology and Transfusion Medicine of the Ams of Ukraine
Lviv, Ukraine
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Jun 2007
- Primary completion
- 11 Nov 2010
- Completion
- 17 May 2018
- Last update posted
- 11 Feb 2020
- Registered enrollment
- 131
- Registry id
- NCT00426764
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.